Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 11;12(1):e12127.
doi: 10.1002/dad2.12127. eCollection 2020.

Quantitative informant- and self-reports of subjective cognitive decline predict amyloid beta PET outcomes in cognitively unimpaired individuals independently of age and APOE ε4

Gonzalo Sánchez-Benavides  1   2   3 , Gemma Salvadó  1   2 , Eider M Arenaza-Urquijo  1   2   3 , Oriol Grau-Rivera  1   2   3   4 , Marc Suárez-Calvet  1   2   3   4 , Marta Milà-Alomà  1   2   3   5 , José María González-de-Echávarri  1   2   3 , Carolina Minguillon  1   2   3 , Marta Crous-Bou  1   6   7 , Aida Niñerola-Baizán  8 , Andrés Perissinotti  8 , Juan Domingo Gispert  1   2   5   9 , José Luis Molinuevo  1   2   3   5 ; ALFA Study
Affiliations

Quantitative informant- and self-reports of subjective cognitive decline predict amyloid beta PET outcomes in cognitively unimpaired individuals independently of age and APOE ε4

Gonzalo Sánchez-Benavides et al. Alzheimers Dement (Amst). .

Abstract

Introduction: Amyloid beta (Aβ) pathology is an Alzheimer's disease early hallmark. Here we assess the value of longitudinal self- and informant reports of cognitive decline to predict Aβ positron emission tomography (PET) outcome in cognitively unimpaired middle-aged individuals.

Methods: A total of 261 participants from the ALFA+ study underwent [18F]flutemetamol PET and Subjective Cognitive Decline Questionnaire (SCD-Q) concurrently, and 3 years before scan. We used logistic regressions to evaluate the ability of SCD-Q scores (self and informant) to predict Aβ PET visual read, and repeated analysis of variance to assess whether changes in SCD-Q scores relate to Aβ status.

Results: Self-perception of decline in memory (odds ratio [OR] = 1.2), and informant perception of executive decline (OR = 1.6), increased the probability of a positive scan. Informant reports 3 years before scanning predicted Aβ PET outcome. Longitudinal increase of self-reported executive decline was predictive of Aβ in women (P = .003).

Discussion: Subjective reports of cognitive decline are useful to predict Aβ and may improve recruitment strategies.

Keywords: Alzheimer's disease; amyloid; informant reports; preclinical; subjective cognitive decline.

PubMed Disclaimer

Conflict of interest statement

José Luis Molinuevo has served/serves as a consultant or on advisory boards for the following for‐profit companies, or has given lectures in symposia sponsored by the following for‐profit companies: Roche Diagnostics, Genentech, Novartis, Lundbeck, Oryzon, Biogen, Lilly, Janssen, Green Valley, MSD, Eisai, Alector, BioCross, GE Healthcare, ProMIS Neurosciences. Juan Domingo Gisper has given lectures in symposia sponsored by the following for‐profit companies: General Electric, Philips, and Biogen. The remaining authors declare that they have no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Odds ratios (ORs) with 95% confidence intervals (CIs) for positive amyloid beta scan prediction using Subjective Cognitive Decline Questionnaire (SCD‐Q) scores. Models were adjusted by age, sex, and APO E ε4 status
See this image and copyright information in PMC

References

    1. Molinuevo JL, Minguillon C, Rami L, Gispert JD. The rationale behind the new Alzheimer's disease conceptualization: lessons learned during the last decades. J Alzheimer's Dis. 2018;62:1067‐1077. - PMC - PubMed
    1. Dubois B, Hampel H, Feldman HH, et al. Preclinical Alzheimer's disease: definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016;12:292‐323. - PMC - PubMed
    1. Jack CR, Bennett DA, Blennow K, et al. NIA‐AA Research Framework: toward a biological definition of Alzheimer's disease. Alzheimer's Dement. 2018;14:535‐562. - PMC - PubMed
    1. Bateman RJ, Fagan AM, Holtzman DM, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012;367:795‐804. - PMC - PubMed
    1. Golde BTE, Dekosky ST, Galasko D. Alzheimer's disease: the right drug, the right time. Science. 2018;362:1250‐1252. - PubMed